Literature DB >> 22990666

CCR7+ central and CCR7- effector memory CD4+ T cells in human cutaneous leishmaniasis.

Hossein Keshavarz Valian1, Mahmoud Nateghi Rostami, Minoo Tasbihi, Akram Miramin Mohammadi, Seyed Ebrahim Eskandari, Abdolfattah Sarrafnejad, Ali Khamesipour.   

Abstract

PURPOSE: The profile of central (=T(CM)) and effector (=T(EM)) memory CD4(+) T cell subsets and the possible role as surrogate markers of protection is studied in the volunteers with history of cutaneous leishmaniasis (HCL).
METHODS: Profile of T cell subsets based on CCR7/CD45RA expressions and phenotypic changes after soluble Leishmania antigen (SLA) stimulation were analyzed. Then, sorted CD4(+)CD45RO(-)CD45RA(+) naïve T, CD4(+)CD45RO(+)CD45RA(-)CCR7(-) T(EM,) CD4(+)CD45RO(+)CD45RA(-)CCR7(+) T(CM) subsets were cultured with SLA for proliferation, cytokine production and intracellular cytokine assays.
RESULTS: In the HCL and control volunteers, the mean frequencies of CD4(+)CD45RA(+)CCR7(+) naïve T cells and CD4(+)CD45RA(-)CCR7(-) T(EM) cells were higher than the other subsets before culture. Frequency of naïve T cells and CD4(+)CD45RA(-)CCR7(+) T(CM) cells was significantly decreased (P=0.01 for naïve T and P<0.05 for T(CM) cells) and frequency of T(EM) cells was significantly increased after SLA stimulation compared to before culture (P<0.001). By CFSE labeling, CD4(+)CD45RO(+)CD45RA(-)CCR7(+) T(CM) cells showed more proliferation potential than CD4(+)CD45RO(+)CD45RA(-)CCR7(-) T(EM) cells. Stimulation of the T(EM) cells in HCL volunteers induced a significantly higher IFN-γ production (P=0.04) with higher number of intracellular IFN-γ positive cells (P=0.032) than the same cells from controls. A significantly higher number of T(CM) cells produced IL-2 in HCL volunteers compared with controls (P<0.05). Most of the intracellular IFN-γ positive T(EM) cells were proliferating CFSE-dim populations (P<0.05).
CONCLUSIONS: A combination of Leishmania-reactive IFN-γ producing CD4(+)CD45RO(+)CD45RA(-)CCR7(-) T(EM) and Leishmania-reactive IL-2 producing CD4(+)CD45RO(+)CD45RA(-)CCR7(+) T(CM) are identified in individuals with history of CL which might play a role in protective recall immune response against Leishmania infection.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22990666     DOI: 10.1007/s10875-012-9788-7

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  51 in total

Review 1.  Human CD8(+) T-cell differentiation in response to viruses.

Authors:  René A W van Lier; Ineke J M ten Berge; Laila E Gamadia
Journal:  Nat Rev Immunol       Date:  2003-12       Impact factor: 53.106

Review 2.  Induction, regulation and function of T-cell subsets in leishmaniasis.

Authors:  F Y Liew
Journal:  Chem Immunol       Date:  1992

Review 3.  Similarities and differences in CD4+ and CD8+ effector and memory T cell generation.

Authors:  Robert A Seder; Rafi Ahmed
Journal:  Nat Immunol       Date:  2003-09       Impact factor: 25.606

Review 4.  Heterogeneity of CD4+ memory T cells: functional modules for tailored immunity.

Authors:  Federica Sallusto; Antonio Lanzavecchia
Journal:  Eur J Immunol       Date:  2009-08       Impact factor: 5.532

5.  Immune response of BALB/c mice against an experimental vaccine of Alum precipitated autoclaved Leishmania major (Alum-ALM) mixed with BCG or Mycobacterium vaccae.

Authors:  M Nateghi Rostami; H Keshavarz; A Khamesipour
Journal:  Trop Biomed       Date:  2010-04       Impact factor: 0.623

6.  Analysis of memory T cells in the human paracoccidioidomycosis before and during chemotherapy treatment.

Authors:  A Bozzi; B S Reis; M I Goulart; M C N Pereira; E P Pedroso; A M Goes
Journal:  Immunol Lett       Date:  2007-09-11       Impact factor: 3.685

Review 7.  T cell memory in malaria.

Authors:  Ian A Cockburn; Fidel Zavala
Journal:  Curr Opin Immunol       Date:  2007-07-12       Impact factor: 7.486

8.  Immune response measured in human volunteers vaccinated with autoclaved Leishmania major vaccine mixed with low dose of BCG.

Authors:  M Mahmoodi; A Khamesipour; Y Dowlati; S Rafati; A Z Momeni; M Emamjomeh; H Hejazi; F Modabber
Journal:  Clin Exp Immunol       Date:  2003-11       Impact factor: 4.330

Review 9.  First generation leishmaniasis vaccines: a review of field efficacy trials.

Authors:  Sassan Noazin; Farrokh Modabber; Ali Khamesipour; Peter G Smith; Lawrence H Moulton; Kiumarss Nasseri; Iraj Sharifi; Eltahir A G Khalil; Ivan Dario Velez Bernal; Carlos M F Antunes; Marie Paule Kieny; Marcel Tanner
Journal:  Vaccine       Date:  2008-10-23       Impact factor: 3.641

10.  Chemokine receptor expression identifies Pre-T helper (Th)1, Pre-Th2, and nonpolarized cells among human CD4+ central memory T cells.

Authors:  Laura Rivino; Mara Messi; David Jarrossay; Antonio Lanzavecchia; Federica Sallusto; Jens Geginat
Journal:  J Exp Med       Date:  2004-09-20       Impact factor: 14.307

View more
  12 in total

1.  Effector memory CD4(+) T cells differentially express activation associated molecules depending on the duration of American cutaneous leishmaniasis lesions.

Authors:  C de Oliveira Mendes-Aguiar; R Vieira-Gonçalves; L H Guimarães; M P de Oliveira-Neto; E M Carvalho; A M Da-Cruz
Journal:  Clin Exp Immunol       Date:  2016-06-06       Impact factor: 4.330

Review 2.  Memory T cells in cutaneous leishmaniasis.

Authors:  Nelson D Glennie; Phillip Scott
Journal:  Cell Immunol       Date:  2016-07-16       Impact factor: 4.868

3.  American tegumentary leishmaniasis: T-cell differentiation profile of cutaneous and mucosal forms-co-infection with Trypanosoma cruzi.

Authors:  Cecilia Parodi; María F García Bustos; Alejandra Barrio; Federico Ramos; Ana G González Prieto; María C Mora; Patricia Baré; Miguel A Basombrío; María M de Elizalde de Bracco
Journal:  Med Microbiol Immunol       Date:  2016-04-04       Impact factor: 3.402

Review 4.  Potential biomarkers of immune protection in human leishmaniasis.

Authors:  Mahmoud Nateghi Rostami; Ali Khamesipour
Journal:  Med Microbiol Immunol       Date:  2021-05-02       Impact factor: 3.402

Review 5.  The History of Live Attenuated Centrin Gene-Deleted Leishmania Vaccine Candidates.

Authors:  Greta Volpedo; Parna Bhattacharya; Sreenivas Gannavaram; Thalia Pacheco-Fernandez; Timur Oljuskin; Ranadhir Dey; Abhay R Satoskar; Hira L Nakhasi
Journal:  Pathogens       Date:  2022-04-02

6.  Immunologic response and memory T cells in subjects cured of tegumentary leishmaniasis.

Authors:  Augusto M Carvalho; Andréa Magalhães; Lucas P Carvalho; Olívia Bacellar; Phillip Scott; Edgar M Carvalho
Journal:  BMC Infect Dis       Date:  2013-11-09       Impact factor: 3.090

7.  Role of TEFFECTOR/MEMORY Cells, TBX21 Gene Expression and T-Cell Homing Receptor on Type 1 Reaction in Borderline Lepromatous Leprosy Patients.

Authors:  Luciana Nahar Dos Santos; Pedro Henrique Lopes da Silva; Iris Maria Peixoto Alvim; José Augusto da Costa Nery; Flávio Alves Lara; Euzenir Nunes Sarno; Danuza Esquenazi
Journal:  PLoS One       Date:  2016-10-20       Impact factor: 3.240

8.  Phenotypic and Functional Profiles of Antigen-Specific CD4+ and CD8+ T Cells Associated With Infection Control in Patients With Cutaneous Leishmaniasis.

Authors:  Adriana Egui; Darién Ledesma; Elena Pérez-Antón; Andrés Montoya; Inmaculada Gómez; Sara María Robledo; Juan José Infante; Ivan Darío Vélez; Manuel C López; M Carmen Thomas
Journal:  Front Cell Infect Microbiol       Date:  2018-11-19       Impact factor: 5.293

Review 9.  Cutaneous Leishmaniasis Vaccination: A Matter of Quality.

Authors:  Paula Mello De Luca; Amanda Beatriz Barreto Macedo
Journal:  Front Immunol       Date:  2016-04-21       Impact factor: 7.561

10.  Design of multi-epitope peptides containing HLA class-I and class-II-restricted epitopes derived from immunogenic Leishmania proteins, and evaluation of CD4+ and CD8+ T cell responses induced in cured cutaneous leishmaniasis subjects.

Authors:  Sarra Hamrouni; Rachel Bras-Gonçalves; Abdelhamid Kidar; Karim Aoun; Rym Chamakh-Ayari; Elodie Petitdidier; Yasmine Messaoudi; Julie Pagniez; Jean-Loup Lemesre; Amel Meddeb-Garnaoui
Journal:  PLoS Negl Trop Dis       Date:  2020-03-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.